Systemic lupus erythematous and clinical outcomes in peritoneal dialysis

Massignan, B; Figueiredo, Ana Elizabeth; Barretti, Pasqual; Olandoski, Márcia; Kirk, Adam; Pecoits‐Filho, Roberto

doi:10.1177/0961203314555353

Cited by 5 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There appear to be no differences according to the primary disease, even with lupus nephritis or polycystic kidney disease [413,414]. A retrospective study on the incidence of peritonitis in Japan in 1996 reported a value of 0.23/patient/year [415].…”

Section: Explanationmentioning

confidence: 99%

Peritoneal Dialysis Guidelines 2019 Part 1 (Position paper of the Japanese Society for Dialysis Therapy)

et al. 2021

View full text Add to dashboard Cite

Approximately 10 years have passed since the Peritoneal Dialysis Guidelines were formulated in 2009. Much evidence has been reported during the succeeding years, which were not taken into consideration in the previous guidelines, e.g., the next peritoneal dialysis PD trial of encapsulating peritoneal sclerosis (EPS) in Japan, the significance of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), the effects of icodextrin solution, new developments in peritoneal pathology, and a new international recommendation on a proposal for exit-site management. It is essential to incorporate these new developments into the new clinical practice guidelines. Meanwhile, the process of creating such guidelines has changed dramatically worldwide and differs from the process of creating what were “clinical practice guides.” For this revision, we not only conducted systematic reviews using global standard methods but also decided to adopt a two-part structure to create a reference tool, which could be used widely by the society’s members attending a variety of patients. Through a working group consensus, it was decided that Part 1 would present conventional descriptions and Part 2 would pose clinical questions (CQs) in a systematic review format. Thus, Part 1 vastly covers PD that would satisfy the requirements of the members of the Japanese Society for Dialysis Therapy (JSDT). This article is the duplicated publication from the Japanese version of the guidelines and has been reproduced with permission from the JSDT.

show abstract

Section: Explanationmentioning

confidence: 99%

Peritoneal Dialysis Guidelines 2019 Part 1 (Position paper of the Japanese Society for Dialysis Therapy)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Liver cancer is the sixth most common cancer worldwide, accounting for 5.6% of the total cases diagnosed in 2012 (1)(2)(3)(4).…”

Section: Introductionmentioning

confidence: 99%

“…In developed countries, liver cancer is the sixth leading cause of cancer-associated mortality among men. In 2012, an estimated 782,000 new liver cancer cases and 745,000 deaths occurred globally, with >50% of the total cases and deaths reported in China (2)(3)(4)(5). In China, liver cancer is the fourth most common cancer and the third leading cause of cancer-associated mortality (5).…”

Section: Introductionmentioning

confidence: 99%

Tannic acid synergistically enhances the anticancer efficacy of cisplatin on liver cancer cells through mitochondria‑mediated apoptosis

Geng

Zheng

et al. 2019

Oncol Rep

View full text Add to dashboard Cite

Cisplatin (cis-dichlorodiamine platinum, CDDP) is a potent antitumor agent. However, its clinical application is limited by its side effects and the development of drug resistance. Tannic acid (TA) has previously been reported to suppress tumor growth in different types of cancer. The present study evaluated the anticancer efficacy of TA in combination with CDDP on the liver cancer cell line HepG2, and investigated the associated underlying molecular mechanisms. The results revealed that treatment with TA or CDDP alone inhibited HepG2 cell growth, with a half maximal inhibitory concentration of 360 µM and 1.8 µg/ml, respectively. The combination of TA and CDDP induced mitochondria-mediated apoptosis in HepG2 cells and significantly enhanced the growth inhibitory effect compared with TA or CDDP treatment alone. The results obtained from the present study suggest that the combination of TA and CDDP may exert synergistic anticancer effects and may be a novel adjuvant treatment for liver cancer.

show abstract

“…Several studies have reported that patients with LN undergoing PD have a poor prognosis associated with higher hospitalization and infection rates (2–4). However, a prospective observational study from the BRAZPD II cohort showed that systemic lupus erythematosus (SLE) patients on PD had similar patient and technique survival (5). The controversial results may be mainly attributed to the selection bias in different districts, different socio-economic situations and follow-up periods (6).…”

mentioning

confidence: 99%

Long-Term Clinical Outcomes of Lupus Nephritis Patients Undergoing Peritoneal Dialysis: A Matched, Case-Control Study

Cao

Lin

et al. 2019

Perit Dial Int

View full text Add to dashboard Cite

The long-term clinical outcomes of peritoneal dialysis (PD) for patients with lupus nephritis (LN) have not been well researched. In the present study, we investigated the long-term prognosis of a Chinese PD cohort. This was a retrospective case-control study that included LN patients receiving PD treatment for more than 90 days from January 2006 to December 2012. Non-diabetic control patients were selected using a ratio of 1:2 for age- and gender-matching. The primary outcome was all-cause mortality. Secondary outcomes included technique failure and hospitalization rate. All patients were followed up to 31 December 2017. A total of 28 LN patients on PD (89.3% female, mean age 42.2±15.8 years) and 56 controls were included. After a median follow-up period of 53.1 months, 11 LN patients died. The cumulative 1-, 3-, and 5-year patient survival rates were 92.4%, 84.7%, and 67.6% in LN patients, and 100%, 93.5%, and 82.9% in the control group, respectively ( p = 0.035). After adjusting for confounders, LN was not significantly associated with mortality (hazard ratio [HR]: 1.39, 95% confidence interval [CI]: 0.45 – 4.26); However, LN was still an independent risk factor of technique failure (HR: 2.87, 95% CI: 1.08 – 7.66). Meanwhile, the LN group had significantly higher hospitalization and infection rates. In conclusion, LN patients undergoing PD had poor patient survival and technique survival, and higher hospitalization and infection rates.

show abstract

Systemic lupus erythematous and clinical outcomes in peritoneal dialysis

Abstract: PD therapy was shown to be a safe and equally successful therapy for SLE patients compared to matched non-SLE patients.

Cited by 5 publications

References 23 publications

Peritoneal Dialysis Guidelines 2019 Part 1 (Position paper of the Japanese Society for Dialysis Therapy)

Peritoneal Dialysis Guidelines 2019 Part 1 (Position paper of the Japanese Society for Dialysis Therapy)

Tannic acid synergistically enhances the anticancer efficacy of cisplatin on liver cancer cells through mitochondria‑mediated apoptosis

Long-Term Clinical Outcomes of Lupus Nephritis Patients Undergoing Peritoneal Dialysis: A Matched, Case-Control Study

Contact Info

Product

Resources

About